Compugen Ltd.
72 Pinchas Rosen Street
Tel Aviv
69512
Tel: 972-3-765-8585
Fax: 972-3-765-8555
Website: http://www.cgen.com/
Email: info@cgen.com
384 articles with Compugen Ltd.
-
Compugen to Present at Upcoming Industry Conferences
6/27/2022
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that members of its management team will present at the following industry conferences in Europe.
-
Compugen to Present at Upcoming Investor Conferences - June 01, 2022
6/1/2022
Compugen Ltd., a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced that management will present at the following investor conferences.
-
Compugen Reports First Quarter 2022 Results
5/16/2022
Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today financial results for the first quarter ended March 31, 2022 and provided a corporate update on key events since the start of 2022.
-
Genentech's flop of its anti-TIGIT drug has cast a shadow of doubt over the numerous companies in the process of developing their own anti-TIGIT drugs.
-
Compugen Announces CFO Departure
5/10/2022
Compugen Ltd. announced that Mr. Ari Krashin, Chief Financial Officer and Chief Operating Officer of Compugen Ltd., notified the Company of his wish to depart from his position at the Company to pursue other interests.
-
Compugen to Release First Quarter 2022 on Monday, May 16, 2022
5/2/2022
Compugen Ltd. announced today that the Company will release its first quarter 2022 financial results on Monday, May 16, 2022 before the U.S. financial markets open.
-
Compugen's Computational Discovery Leverages Single Cell Spatial Transcriptomics to Gain In-Depth Understanding of the Tumor Microenvironment
3/21/2022
Compugen Ltd. today announced that it will give a presentation today on exploring the immune-tumor microenvironment (TME) using high resolution single-cell spatial transcriptomics at the Keystone Symposium.
-
Compugen To Present New Insights into the Tumor Microenvironment Using Single Cell Spatial Transcriptomics at Keystone Symposium
3/14/2022
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it has been selected to give an oral presentation on exploring the immune-tumor microenvironment using high resolution single-cell spatial transcriptomics at the Keystone Symposium on Cancer Immunotherapy to take place on March 20-24, 2022.
-
Compugen to Present at the Oppenheimer 32nd Annual Global Healthcare Conference
3/9/2022
Compugen Ltd. today announced that management will present at the Oppenheimer 32nd Annual Global Healthcare Conference (virtual), on Wednesday, March 16, 2022 at 11:20 am ET .
-
Compugen Presents New Research Suggesting Targeting DNAM-1 Axis Holds Promise for Treatment of Multiple Myeloma
3/9/2022
Compugen Ltd. today announced the presentation of new research suggesting that targeting PVRIG and TIGIT holds promise for treating multiple myeloma.
-
Compugen Reports Fourth Quarter and Full Year 2021 Results
2/24/2022
Compugen Ltd., a clinical-stage cancer immunotherapy company and leader in predictive target discovery, reported financial results for the fourth quarter ended December 31, 2021, and full year 2021 and provided an update on recent Company highlights.
-
Compugen Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors
2/24/2022
Compugen Ltd. announced today the appointment of Mathias Hukkelhoven, Ph.D., formerly Senior Vice President, Global Regulatory, Safety & Biometrics at Bristol Myers Squibb, to its Board of Directors.
-
Compugen to Release Fourth Quarter and Full Year 2021 Results on Thursday, February 24, 2022
2/10/2022
Compugen Ltd. announced today that the Company will release its fourth quarter and full year 2021 financial results on Thursday, February 24, 2022 , before the U.S. financial markets open.
-
Compugen to Present at the 11th Annual SVB Leerink Global Healthcare Conference
2/9/2022
Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced that management will present at the 11th Annual SVB Leerink Global Healthcare Conference, on Wednesday, February 16, 2022 at 12:00 pm ET.
-
Compugen Presents Preliminary Translational Data Demonstrating Immune Activation in the Tumor Microenvironment by COM701 at the TIGIT Therapies Digital Summit
12/9/2021
Compugen Ltd. today announced the presentation of preliminary translational data from patient biopsies demonstrating immune activation in the tumor microenvironment (TME) after treatment with COM701, Compugen's potentially first-in-class anti-PVRIG antibody, as a monotherapy and in combination with nivolumab at the TIGIT Therapies Digital Summit.
-
Compugen Reports Third Quarter 2021 Results
11/12/2021
Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, reported financial results for the third quarter ended September 30, 2021.
-
Compugen to Present at Upcoming Investor Conferences - Nov 08, 2021
11/8/2021
Compugen Ltd. a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced that management will present at the following investor conferences.
-
Compugen to Release Third Quarter 2021 Results on Friday, November 12, 2021
10/26/2021
Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced that the Company will release its third quarter 2021 financial results on Friday, November 12, 2021, before the U.S. financial markets open.
-
Compugen Announces Milestone Payment from AstraZeneca Triggered by First Patient Dosed with TIGIT Bispecific Derived from COM902
10/4/2021
Compugen Ltd. (NASDAQ: CGEN), today announced that Compugen is entitled to receive a $6 million milestone payment from AstraZeneca (LSE: AZN) (STO: AZN) (Nasdaq: AZN) triggered by the dosing of the first patient in a Phase 1/2 study evaluating AZD2936, a TIGIT/PD-1 bispecific antibody, in patients with advanced or metastatic non-small cell lung cancer.
-
Compugen to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
8/26/2021
Compugen Ltd. today announced that management will present at the Morgan Stanley 19th Annual Global Healthcare Conference (virtual), on Thursday, September 9, 2021 at 11:00 am ET .